CLDI — Calidi Biotherapeutics, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1855485 ·
Last close
$1.13
Market Cap
$2.92M
52W High
$27.84
52W Low
$1.05
ADV30
183,493
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,150,000 | -4,160,000 | 7,204,000 | 4,071,000 | 4,071,000 |
| Mar 2026 | 0 | — | -4,187,000 | -4,108,000 | 9,591,000 | 6,631,000 | 4,656,000 |
| Dec 2025 | 0 | — | -4,466,000 | -4,056,000 | 8,857,000 | 5,600,000 | 5,098,000 |
| Sep 2025 | 0 | — | -5,048,000 | -5,149,000 | 14,029,000 | 10,375,000 | 6,831,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,278,000
Investing CF
$-168,000
Financing CF
$14,510,000
CapEx
$-118,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-109.44
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-145,729,000
Inventory
—
Receivables
$50,000
ST Investments
—
EBIT TTM
$-18,920,000
Pretax Income TTM
$-19,093,000
Interest Exp TTM
$173,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,190,000 | -19,906,000 | 8,857,000 | 5,098,000 | 3,759,000 | -21,293,000 |
| Dec 2024 | 0 | -21,595,000 | -22,143,000 | 14,182,000 | 12,214,000 | 1,534,000 | -19,694,000 |
| Dec 2023 | 0 | -26,107,000 | -29,216,000 | 10,019,000 | 18,254,000 | -8,235,000 | -26,983,000 |
| Dec 2022 | 45,000 | -23,128,000 | -25,427,000 | 2,597,000 | 53,037,000 | -50,440,000 | -13,214,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VIVS | VivoSim Labs, INC. | $2.95M | $0.22 | — |
| BCAB | BioAtla, Inc. | $2.47M | $1.48 | — |
| ABPO | Abpro Holdings, Inc. | $2.42M | $0.41 | — |
| CRIS | CURIS INC | $2.01M | $0.83 | — |
| PMCB | PharmaCyte Biotech, Inc. | $4.73M | $0.44 | — |
News headlines (Yahoo Finance, 1h cache)
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
2026-09-25 21:00 · Yahoo
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-13 20:30 · Yahoo
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conferen
2026-07-27 12:00 · Yahoo
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
2026-07-20 20:30 · Yahoo
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
2026-06-23 12:00 · Yahoo
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study
2026-06-16 12:00 · Yahoo
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9
2026-06-05 16:00 · Yahoo
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting
2026-05-26 12:00 · Yahoo
Calidi Biotherapeutics Provides Required NYSE American Disclosure
2026-05-22 22:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.